Pre-Open Stock Movers

ChemoCentryx, Inc., (NASDAQ: CCXI) 324% HIGHER; ChemoCentryx and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced positive topline data from the pivotal Phase III ADVOCATE trial of avacopan, an orally-administered selective complement 5a receptor inhibitor, for the treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (ANCA-associated vasculitis or ANCA vasculitis).

Nutanix (NASDAQ: NTNX) 18.9% HIGHER; reported Q1 EPS of ($0.71), $0.04 better than the analyst estimate of ($0.75). Revenue for the quarter came in at $314.8 million versus the consensus estimate of $306.41 million. Nutanix sees Q2 2020 EPS of ($0.70), versus the consensus of ($0.70). Nutanix sees Q2 2020 revenue of $410-420 million, versus the consensus of $336.4 million. Nutanix sees FY2020 revenue of $1.65-1.75 billion, versus the consensus of $1.38 billion.

Movado Group (NYSE: MOV) 19.6% LOWER; reported Q3 EPS of $0.82, $0.21 worse than the analyst estimate of $1.03. Revenue for the quarter came in at $205.6 million versus the consensus estimate of $220 million (1 analyst). Movado Group sees FY2020 revenue of $690-700 million, versus the consensus of $729.4 million.

Dollar Tree (NASDAQ: DLTR) 13.4% LOWER; reported Q3 EPS of $1.08, $0.05 worse than the analyst estimate of $1.13. Revenue for the quarter came in at $5.75 billion versus the consensus estimate of $5.74 billion. Dollar Tree sees Q4 2019 EPS of $1.70-$1.80, versus the consensus of $2.02. Dollar Tree sees Q4 2019 revenue of $6.33-6.44 billion, versus the consensus of $6.41 billion. Dollar Tree sees FY2019 EPS of $4.66-$4.76, versus the consensus of $5.05. Dollar Tree sees FY2019 revenue of $23.62-23.74 billion, versus the consensus of $23.74 billion.

Dick's Sporting Goods (NYSE: DKS) 11% HIGHER; reported Q3 EPS of $0.52, $0.15 better than the analyst estimate of $0.37. Revenue for the quarter came in at $1.96 billion versus the consensus estimate of $1.91 billion. Consolidated same store sales for the third quarter increased 6.0%. Dick's Sporting Goods sees FY2019 EPS of $3.63-$3.73, versus the consensus of $3.41.

InflaRx N.V. (NASDAQ: IFRX) 11% HIGHER; up in with CCXI

Global Blood Therapeutics, Inc. (NASDAQ: GBT) 10.6% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Oxbryta (voxelotor) tablets for the treatment of sickle cell disease (SCD) in adults and children 12 years of age and older.1 Oxbryta, an oral therapy taken once daily, is the first approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of SCD.2,3 The medicine is expected to be available through GBTs specialty pharmacy partner network within two weeks.

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) 9.4% LOWER; announced today that it has commenced an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof) and Class B warrants to purchase its common stock. All of the securities in the offering will be sold by X4. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

Caleres (NYSE: CAL) 9.5% LOWER; reported Q3 EPS of $0.78, $0.05 worse than the analyst estimate of $0.83. Revenue for the quarter came in at $792.4 million versus the consensus estimate of $820.42 million. Caleres sees FY2019 EPS of $2.35-$2.40, versus the consensus of $2.40.

Palo Alto Networks (NYSE: PANW) 7.9% LOWER; reported Q1 EPS of $1.05, $0.02 better than the analyst estimate of $1.03. Revenue for the quarter came in at $771.9 million versus the consensus estimate of $767.77 million. Palo Alto Networks sees Q2 2020 EPS of $1.11-$1.13, versus the consensus of $1.30. Palo Alto Networks sees Q2 2020 revenue of $838-848 million, versus the consensus of $845.12 million. Palo Alto Networks sees FY2020 EPS of $4.90-$5.00, versus the consensus of $5.07. Palo Alto Networks sees FY2020 revenue of $3.44-3.48 billion, versus the consensus of $3.46 billion.

Chesapeake Energy (NYSE: CHK) 5.2% HIGHER; Scotiabank analyst Matthew Sorenson upgraded from Sector Perform to Sector Outperform.

Beacon Roofing Supply (NASDAQ: BECN) 4.2% LOWER; reported Q4 EPS of $1.04, $0.17 worse than the analyst estimate of $1.21. Revenue for the quarter came in at $2.03 billion versus the consensus estimate of $2.05 billion.

Best Buy (NYSE: BBY) 4% HIGHER; reported Q3 EPS of $1.13, $0.10 better than the analyst estimate of $1.03. Revenue for the quarter came in at $9.76 billion versus the consensus estimate of $9.7 billion. Enterprise Comparable Sales Increased 1.7%. Best Buy sees Q4 EPS of $2.65-$2.75, versus the consensus of $2.65. Best Buy sees Q4 revenue of $14.75-15.15 billion, versus the consensus of $15 billion. Best Buy sees FY2020 EPS of $5.81-$5.91, versus the consensus of $5.74. Best Buy sees FY2020 revenue of $43.2-43.6 billion, versus the consensus of $43.38 billion.

Hewlett Packard Enterprise (NYSE: HPE) 3.7% LOWER; reported Q4 EPS of $0.49, $0.03 better than the analyst estimate of $0.46. Revenue for the quarter came in at $7.2 billion versus the consensus estimate of $7.4 billion. Hewlett Packard Enterprise sees Q1 2020 EPS of $0.42-$0.46, versus the consensus of $0.42.

AVEO Oncology (NASDAQ: AVEO) 2.9% HIGHER; CEO Michael Bailey disclosed the purchase of 150,000 shares on 11/21 at $0.5973.

Agilent Technologies (NYSE: A) 2.8% LOWER; reported Q4 EPS of $0.89, $0.04 better than the analyst estimate of $0.85. Revenue for the quarter came in at $1.37 billion versus the consensus estimate of $1.33 billion. Agilent Technologies sees FY2020 EPS of $3.38-$3.43, versus the consensus of $3.44. Agilent Technologies sees FY2020 revenue of $5.5-5.55 billion, versus the consensus of $5.55 billion.